keyword
MENU ▼
Read by QxMD icon Read
search

Ivabradine AND Heart failure

keyword
https://www.readbyqxmd.com/read/29161389/innovations-in-management-of-cardiac-disease-drugs-treatment-strategies-and-technology
#1
P Foëx
Within the last generation, the management of patients with heart disease has been transformed by advances in drug treatments, interventions and diagnostic technologies. The management of arterial hypertension saw beta-blockers demoted from first- to third-line treatment. Recent studies suggest that the goal of treatment may have to change to lower systolic blood pressures to prevent long-term organ damage. Today less than 15% of coronary revascularizations are surgical and more than 85% are done by interventional cardiologists inserting coronary stents...
December 1, 2017: British Journal of Anaesthesia
https://www.readbyqxmd.com/read/29142810/the-role-of-ivabradine-in-diastolic-heart-failure-with-preserved-ejection-fraction-a-doppler-echocardiographic-study
#2
Federico Cacciapuoti, Valerio Massimo Magro, Michele Caturano, Diana Lama, Fulvio Cacciapuoti
Background: Ivabradine (IVA) is effective in patients with coronary artery disease (CAD) or systolic heart failure in sinus rhythm. Its action consists in reducing heart rate (HR) and improving the time of left ventricular (LV) diastolic filling. The aim of this study was to evaluate the effects of IVA added to conventional therapy on patients with diastolic heart failure (DHF) and preserved ejection fraction (HFpEF). Methods: We evaluated 25 patients with DHF in the New York Heart Association (NYHA) Class II-III and sinus rhythm...
October 2017: Journal of Cardiovascular Echography
https://www.readbyqxmd.com/read/29121737/ivabradine-well-tolerated-in-elderly-patients-with-systolic-heart-failure
#3
EDITORIAL
Christos Zivlas, Paul W X Foley
No abstract text is available yet for this article.
December 15, 2017: International Journal of Cardiology
https://www.readbyqxmd.com/read/29121732/quality-of-life-improvement-in-older-patients-with-heart-failure-initiated-on-ivabradine-results-from-the-uk-multi-centre-live-life-prospective-cohort-study
#4
D Zachariah, D Stevens, G Sidorowicz, C Spooner, N Rowell, J Taylor, R Kay, M S Salek, P R Kalra
AIMS: LIVE:LIFE is a multi-centre, open-label, prospective observational cohort study assessing health-related quality of life (HRQoL) in older patients with chronic heart failure (CHF) following initiation of ivabradine. The primary endpoint is change in Minnesota Living with Heart Failure Questionnaire (MLWHFQ) total score after 6months. METHODS AND RESULTS: Consenting patients aged ≥70years with CHF, in whom ivabradine was initiated within its licensed indication, were enrolled...
December 15, 2017: International Journal of Cardiology
https://www.readbyqxmd.com/read/29098508/pharmacological-heart-rate-lowering-in-patients-with-a-preserved-ejection-fraction-review-of-a-failing-concept
#5
REVIEW
Markus Meyer, Mehdi Rambod, Martin LeWinter
Epidemiological studies have demonstrated that high resting heart rates are associated with increased mortality. Clinical studies in patients with heart failure and reduced ejection fraction have shown that heart rate lowering with beta-blockers and ivabradine improves survival. It is therefore often assumed that heart rate lowering is beneficial in other patients as well. Here, we critically appraise the effects of pharmacological heart rate lowering in patients with both normal and reduced ejection fraction with an emphasis on the effects of pharmacological heart rate lowering in hypertension and heart failure...
November 3, 2017: Heart Failure Reviews
https://www.readbyqxmd.com/read/29027608/ivabradine-in-postural-orthostatic-tachycardia-syndrome-preliminary-experience-in-children
#6
Grazia Delle Donne, Ferran Rosés Noguer, Jan Till, Tushar Salukhe, Sanjay K Prasad, Piers E F Daubeney
OBJECTIVE: Ivabradine is a selective and specific inhibitor of the I(f) current in the sinoatrial and atrioventricular nodes. It decreases heart rate and myocardial oxygen consumption at rest and during exercise. It is used in adults for management of heart failure and angina, but promising results have been obtained in postural orthostatic tachycardia syndrome (POTS). There is little experience of ivabradine in childhood, although it is used on a compassionate basis. Our aim was to review our experience of ivabradine in a retrospective evaluation of pediatric patients with POTS...
October 13, 2017: American Journal of Cardiovascular Drugs: Drugs, Devices, and Other Interventions
https://www.readbyqxmd.com/read/29027329/duration-of-chronic-heart-failure-affects-outcomes-with-preserved-effects-of-heart-rate-reduction-with-ivabradine-findings-from-shift
#7
Michael Böhm, Michel Komajda, Jeffrey S Borer, Ian Ford, Christoph Maack, Luigi Tavazzi, Aurélie Moyne, Karl Swedberg
AIMS: In heart failure (HF) with reduced ejection fraction and sinus rhythm, heart rate reduction with ivabradine reduces the composite incidence of cardiovascular death and HF hospitalization. METHODS AND RESULTS: It is unclear whether the duration of HF prior to therapy independently affects outcomes and whether it modifies the effect of heart rate reduction. In SHIFT, 6505 patients with chronic HF (left ventricular ejection fraction of ≤35%), in sinus rhythm, heart rate of ≥70 b...
October 12, 2017: European Journal of Heart Failure
https://www.readbyqxmd.com/read/28958335/the-clinical-use-of-ivabradine
#8
REVIEW
Jacob S Koruth, Anuradha Lala, Sean Pinney, Vivek Y Reddy, Srinivas R Dukkipati
The clinical use of ivabradine has and continues to evolve along channels that are predicated on its mechanism of action. It selectively inhibits the funny current (If) in sinoatrial nodal tissue, resulting in a decrease in the rate of diastolic depolarization and, consequently, the heart rate, a mechanism that is distinct from those of other negative chronotropic agents. Thus, it has been evaluated and is used in select patients with systolic heart failure and chronic stable angina without clinically significant adverse effects...
October 3, 2017: Journal of the American College of Cardiology
https://www.readbyqxmd.com/read/28916091/retraction-notice-to-ivabradine-as-adjuvant-treatment-for-chronic-heart-failure-int-j-cardiol-227-2017-43-50
#9
Carolina C Mizzaci, Gustavo J M Porfírio, André T Vilela, José Cícero S Guillhen, Rachel Riera
No abstract text is available yet for this article.
November 15, 2017: International Journal of Cardiology
https://www.readbyqxmd.com/read/28903983/ivabradine-in-heart-failure-the-representativeness-of-shift-systolic-heart-failure-treatment-with-the-if-inhibitor-ivabradine-trial-in-a-broad-population-of-patients-with-chronic-heart-failure
#10
COMPARATIVE STUDY
Debraj Das, Gianluigi Savarese, Ulf Dahlström, Michael Fu, Jonathan Howlett, Justin A Ezekowitz, Lars H Lund
BACKGROUND: The sinus node inhibitor ivabradine was approved for patients with heart failure (HF) after the ivabradine and outcomes in chronic HF (SHIFT [Systolic Heart Failure Treatment With the IF Inhibitor Ivabradine Trial]) trial. Our objective was to characterize the proportion of patients with HF eligible for ivabradine and the representativeness of the SHIFT trial enrollees compared with those in the Swedish Heart Failure Registry. METHODS AND RESULTS: We examined 26 404 patients with clinical HF from the Swedish Heart Failure Registry and divided them into SHIFT type (left ventricular ejection fraction <40%, New York Heart Association class II-IV, sinus rhythm, and heart rate ≥70 beats per minute) and non-SHIFT type...
September 2017: Circulation. Heart Failure
https://www.readbyqxmd.com/read/28859790/ivabradine-in-children-with-dilated-cardiomyopathy-and-symptomatic-chronic-heart-failure
#11
RANDOMIZED CONTROLLED TRIAL
Damien Bonnet, Felix Berger, Eero Jokinen, Paul F Kantor, Piers E F Daubeney
BACKGROUND: Heart rate reduction as a therapeutic target has been investigated in adults with heart failure (HF). Ivabradine has shown promising efficacy, but has not been evaluated in children. Currently, treatment recommendations for chronic pediatric HF are based mainly on chronic HF guidelines for adults. OBJECTIVES: The authors explored the dose-response relationship of ivabradine in children with dilated cardiomyopathy and symptomatic chronic HF. The primary endpoint was ≥20% reduction in heart rate from baseline without inducing bradycardia or symptoms...
September 5, 2017: Journal of the American College of Cardiology
https://www.readbyqxmd.com/read/28844168/effects-of-heart-rate-reduction-with-ivabradine-on-the-international-%C3%A4-ndex-of-erectile-function-iief-5-in-patients-with-heart-failure
#12
Kadir Uğur Mert, Muhammet Dural, Gurbet Özge Mert, Kemal Iskenderov, Ata Özen
INTRODUCTION: The presence of concomitant erectile dysfunction (ED) with heart failure (HF) is not surprising, because endothelial dysfunction is pathophysiologic signature of both ED and HF. ED significantly and adversely affects quality of life in patients with HF. It was demonstrated that ivabradine treatment can improve endothelial function and ED in experimental models. In this study, we aimed to determine the effect of ivabradine treatment on ED in patients with HF via International Index of Erectile Function (IIEF-5) questionaire...
August 26, 2017: Aging Male: the Official Journal of the International Society for the Study of the Aging Male
https://www.readbyqxmd.com/read/28840572/pharmacologic-management-for-heart-failure-and-emerging-therapies
#13
REVIEW
Diana H Kim, Feng-Ju Chien, Howard J Eisen
PURPOSE OF REVIEW: This review aims to summarize the growing body of literature of HF with reduced ejection fraction (HFrEF) and preserved ejection fraction (HFpEF) with a focus on recent pharmacologics. RECENT FINDINGS: HFrEF continues to be more widely investigated than HFpEF. Ivabradine and combinatorial treatment with sacubitril and valsartan are promising newly approved therapies. Other experimental therapies have emerged, which include Serelaxin, Empagliflozin, Neuregulin, and Omecamtive mecarbil, among others...
August 24, 2017: Current Cardiology Reports
https://www.readbyqxmd.com/read/28764615/cerebral-tuberculosis-in-a-patient-with-systemic-lupus-erythematosus-following-cyclophosphamide-treatment-a-case-report
#14
S Cooray, H Zhang, R Breen, G Carr-White, R Howard, M Cuadrado, D D'Cruz, G Sanna
Central nervous system (CNS) tuberculosis (TB) is a rare but catastrophic event in patients with systemic lupus erythematosus (SLE). Here we report a case of cerebral TB in a patient with lupus myocarditis and nephritis, following cyclophosphamide immunosuppression. To our knowledge this is the first reported case of cerebral TB in SLE in a non-endemic country. A 31-year-old female with SLE and a history of regular travel to Kenya presented to our centre with clinical features of acute heart failure. She was diagnosed with severe lupus myocarditis, and a renal biopsy also confirmed lupus nephritis...
January 1, 2017: Lupus
https://www.readbyqxmd.com/read/28762939/-a-new-insight-on-anti-ischemic-action-of-ivabradine-in-patients-with-stable-angina
#15
Zh D Kobalava, A A Shavarov, G K Kiyakbaev
Increase in heart rate triggers most ischemic episodes due to disbalance between myocardial oxygen delivery and consumption. Furthermore, increased heart rate is a modifiable risk factor in patients with chronic heart failure. Ivabradine reduces heart rate by selectively inhibiting the If current of sinoatrial node cells. Recent studies have shown that ivabradine may reduce myocardial ischaemia and its consequences not only through heart rate reduction, but also because of additional pleiotropic effects. This review summarizes last findings that demonstrate variety of ivabradine actions on coronary blood flow and left ventricular function in patients with ischemic heart disease...
March 2017: Kardiologiia
https://www.readbyqxmd.com/read/28726428/-a-present-view-on-ivabradine-in-the-therapy-of-cardiovascular-diseases
#16
Jiří Slíva
Cardiovascular illnesses belong to diseases with the highest prevalence. They are also the most predominant reason of death in the vast majority of European countries. Hence, the offer of effective treatment of these dis-eases is absolutely crucial. This text focuses on the current therapeutical use of ivabradine in its approved indications - chronic stable angina pectoris and chronic heart failure - in the context of so far published relevant clinical trials.Key words: angina pectoris - bradines - heart failure - If current - ischemic heart disease - ivabradine...
2017: Vnitr̆ní Lékar̆ství
https://www.readbyqxmd.com/read/28656798/limited-role-and-benefit-of-ivabradine-in-the-treatment-of-angina-and-heart-failure-with-reduced-ejection-fraction
#17
Pierre Vladimir Ennezat, Shona Cosgrove, Sylvestre Marechaux, Hélène Bouvaist, Thierry H Le Jemtel, Denis Vital Durand
Ivabradine is an original drug that has been approved in two indications (systolic heart failure and angina). The aim of this short review is to draw the attention of clinician prescribers to the evidence base of ivabradine. Three large randomized trials testing ivabradine versus placebo have been performed. The BEAUTIFUL and SIGNIFY trials were in fact negative in the treatment of angina while the SHIFT trial found a marginal benefit of ivabradine over placebo in the treatment of heart failure. These important results are put into perspective in order to improve the assessment of risk-cost/benefit balances when ivabradine is considered...
June 28, 2017: Acta Cardiologica
https://www.readbyqxmd.com/read/28644179/improving-heart-failure-patient-outcomes-utilizing-guideline-directed-therapy
#18
Beth Towery Davidson, Terri Lynn Allison
Heart failure (HF) prevalence continues to rise and remains a significant burden to patients, caregivers, providers, and the healthcare system. Guideline-directed medical therapy with standard neurohormonal blockade has been the cornerstone of medical management for many years. Despite aggressive utilization of angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, beta-blockers, and aldosterone antagonists, HF hospitalizations and readmissions are common and residual mortality remains high...
July 21, 2017: Nurse Practitioner
https://www.readbyqxmd.com/read/28627809/ivabradine-reduces-digitalis-induced-ventricular-arrhythmias
#19
Gerrit Frommeyer, Jan Weller, Christian Ellermann, Nils Bögeholz, Patrick Leitz, Dirk G Dechering, Simon Kochhäuser, Kristina Wasmer, Lars Eckardt
The I(f) channel inhibitor ivabradine is recommended for treatment of heart failure but also affects potassium currents and thereby prolongs ventricular repolarization. The aim of this study was to examine the electrophysiological effects of ivabradine on digitalis-induced ventricular arrhythmias. Thirteen rabbit hearts were isolated and Langendorff-perfused. After obtaining baseline data, the digitalis glycoside ouabain was infused (0.2 μM). Monophasic action potentials and ECG showed a significant abbreviation of QT interval (-34 ms, p < 0...
June 19, 2017: Basic & Clinical Pharmacology & Toxicology
https://www.readbyqxmd.com/read/28627045/heart-rate-and-its-reduction-in-chronic-heart-failure-and-beyond
#20
REVIEW
Aleksandra Nikolovska Vukadinović, Davor Vukadinović, Jeffrey Borer, Martin Cowie, Michel Komajda, Mitja Lainscak, Karl Swedberg, Michael Böhm
Heart rate (HR) is associated with cardiovascular outcomes in all the stages of the cardiovascular continuum as well as in patients with pulmonary, cerebrovascular, and renal disease, sepsis, cancer, and erectile dysfunction. In patients with cardiovascular disease, but also in the general population, increased HR represents an important indicator of mortality with each acceleration of HR over 70 b.p.m. increasing the risk. In patients in sinus rhythm with chronic heart failure with reduced ejection fraction (HFrEF), a HR >70 b...
October 2017: European Journal of Heart Failure
keyword
keyword
76071
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"